Keyword: Hutchison China MediTech
Chinese pharmaceutical database PharmCube highlighted 16 possible blockbuster approvals in China in 2018.
AZ and Chi-Med scores early data for savolitinib combos in lung cancer, WuXi AppTec buys a U.S. CRO, FDA clears Sun's Dadra plant.
Nanjing Legend Biotech reported 100% ORR for a CAR-T product, Chi-Med touted fruquintinib's low liver toxicity, Eisai's Lenvima could challenge Bayer's Nexavar and more.
Novartis may face more furor in Korea, Astellas will develop a Prevnar rival with Affinivax, and Lilly and Chi-Med's colorectal cancer med aims for an NDA in China.